

BAXTER INTERNATIONAL INC.
Net Sales
Periods Ending December 31, 2007 and 2006
(unaudited)
(\$ in millions)

	Q4 2007	Q4 2006 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2007	YTD 2006 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience²								
United States	\$579	\$509	14%	14%	\$2,151	\$1,874	15%	15%
International	630	533	18%	6%	2,419	2,006	21%	12%
Total	\$1,209	\$1,042	16%	10%	\$4,570	\$3,880	18%	13%
Medication Delivery								
United States	\$564	\$549	3%	3%	\$2,142	\$2,081	3%	3%
International	591	490	21%	8%	2,089	1,836	14%	5%
Total	\$1,155	\$1,039	11%	5%	\$4,231	\$3,917	8%	4%
Renal								
United States	\$100	\$95	5%	5%	\$388	\$381	2%	2%
International	501	442	13%	4%	1,851	1,684	10%	4%
Total	\$601	\$537	12%	4%	\$2,239	\$2,065	8%	4%
Baxter excluding Transfusion Therapies								
United States	\$1,243	\$1,153	8%	8%	\$4,681	\$4,336	8%	8%
International	1,722	1,465	18%	6%	6,359	5,526	15%	7%
Total	\$2,965	\$2,618	13%	7%	\$11,040	\$9,862	12%	8%
Transfusion Therapies²								
United States	\$31	\$78	(60%)	(60%)	\$139	\$253	(45%)	(45%)
International	13	67	(81%)	(82%)	84	263	(68%)	(70%)
Total	\$44	\$145	(70%)	(70%)	\$223	\$516	(57%)	(58%)
Baxter International Inc.								
United States	\$1,274	\$1,231	3%	3%	\$4,820	\$4,589	5%	5%
International	1,735	1,532	13%	2%	6,443	5,789	11%	4%
Total	\$3,009	\$2,763	9%	3%	\$11,263	\$10,378	9%	4%

1 Prior year sales data has been reclassified to reflect the change that is described in Note 2 below.

2 The Transfusion Therapies (TT) business was sold on February 28, 2007. The results of operations of the TT business were previously reported in the BioScience business. Due to Baxter's actual and expected significant continuing cash flows associated with this business, Baxter continued to include the results of operations of the TT business in the company's results of continuing operations through the divestiture date. The TT totals above include sales of TT products through the date of divestiture, as well as post-divestiture revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.